I wish to learn more about your hospital’s take-up of the rheumatoid arthritis drug Biosimilar Benepali (http://www.pharmatimes.com/news/biogen_launches_enbrel_biosimilar_benepali_in_the_uk_1020383).

Please can you provide information on the following:

1. Total number of patients being treated for rheumatoid arthritis

Between Jan – Dec 2016, there were 419 admissions where the primary diagnosis was rheumatoid arthritis.

1. Total number of patients suitable for Benepali We do not hold this information

1. Total number of patients that have been prescribed Benepali so far Zero

1. Expected number of patients to be on Benepali in 12 months’ time (if predicted) We do not hold this information

Policy on Benepali:

1. Is your hospital automatically switching patients from Etanercept to Benepali? No
2. Are your rheumatologists using Benepali as a first line anti-TNF treatment in TNF-naive patients? No

1. How much do you anticipate saving per year by switching from Etanercept to Benepali?  Not applicable

2. Any other information on decisions made regarding Benepali? None